title: Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.
abstract: OBJECTIVE
  To study changes induced in ocular surface epithelia and the tear film by antiglaucomatous eyedrops. A beta blocker (0.5% timolol) and a novel prostaglandin F(2alpha) metabolite related drug (0.12% unoprostone) were examined in a prospective, randomised fashion.
  
  
  METHODS
  40 patients were randomly assigned to use either 0. 5% timolol (timolol group) or 0.12% unoprostone eyedrops (unoprostone group) twice a day for 24 weeks. In addition to routine ocular examinations, corneal epithelial integrity (vital staining tests, tear film break up time (BUT), anterior fluorometry, specular microscopy) and tear function (Schirmer's test, cotton thread test, tear clearance test (TCT)) were examined before and after the treatment.
  
  
  RESULTS
  Both eyedrops caused significant reduction in intraocular pressure from the baseline levels. No significant changes were noted in corneal integrity in both groups, except a decrease in BUT at 20 weeks in the timolol group. The timolol group demonstrated significant decreases in Schirmer's test, tear clearance test, and tear function index (Schirmer's test value multiplied by clearance test); however, no such changes were noted in the unoprostone group.
  
  
  CONCLUSIONS
  While unoprostone eyedrops caused no adverse effects on the corneal epithelial integrity and tear function, timolol caused significant impairments in tear production and turnover.
authors.affiliation: Department of Ophthalmology, Tokyo Dental College, Chiba, Japan. jun@eyebank.or.jp
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
authors.forename: K
authors.initials: K
authors.lastname: Hanada
authors.forename: Y
authors.initials: Y
authors.lastname: Yagi
authors.forename: J
authors.initials: J
authors.lastname: Yamagami
authors.forename: M
authors.initials: M
authors.lastname: Ishioka
authors.forename: S
authors.initials: S
authors.lastname: Shimmura
authors.forename: K
authors.initials: K
authors.lastname: Tsubota
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000737:chemistry; D000368:Aged; D015237:Dinoprost / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D019573:Epithelium, Corneal / Q000187:drug effects*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D009898:Optic Disk / Q000187:drug effects; D011446:Prospective Studies; D013666:Tears / Q000187:drug effects; D013999:Timolol / Q000008:administration & dosage* / Q000737:chemistry; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; C072630:isopropyl unoprostone; D013999:Timolol; D015237:Dinoprost